Hormonal interactions in endometrial cancer

Area of Science:

• Gynecology
• Oncology
• Endocrinology

Background:

• Endometrial cancer (EC) is the most frequent female genital tract malignancy.
• Evidence indicates at least two distinct types of EC exist, differing in etiology, histology, prognosis, and molecular mechanisms.
• Type I EC is linked to estrogen predominance and endometrioid histology, while Type II EC arises from atrophic endometrium and has serous histology.

Purpose of the Study:

• To review reproductive and lifestyle factors influencing Type I endometrial cancer risk.
• To discuss established and novel therapies for precancerous lesions and invasive EC.
• To explore treatment strategies in both adjuvant and palliative settings.

Main Methods:

• Literature review of reproductive and lifestyle factors associated with Type I EC.
• Analysis of established and novel therapeutic approaches for endometrial cancer and its precursors.
• Discussion of treatment efficacy in adjuvant and palliative care.

Main Results:

• Reproductive and lifestyle factors, including hormonal contraceptives, hormone replacement therapy, and tamoxifen, modify the risk of Type I EC.
• Therapeutic options for precancerous lesions and invasive EC vary based on cancer type and stage.
• Both established and novel therapies show roles in adjuvant and palliative management of EC.

Conclusions:

• Endometrial cancer encompasses distinct subtypes with different risk factors and therapeutic responses.
• Further research into molecular mechanisms and targeted therapies is essential for improving EC management.
• Comprehensive management strategies considering reproductive history and therapeutic options are vital for EC patients.